Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Leukemia
About this trial
This is an interventional treatment trial for Leukemia focused on measuring adult acute myeloid leukemia in remission, childhood acute myeloid leukemia in remission, adult acute promyelocytic leukemia (M3), childhood acute promyelocytic leukemia (M3), adult acute myeloid leukemia with t(15;17)(q22;q12)
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of acute promyelocytic leukemia by positive RT-PCR assay for PML/RAR-alfa rearrangement or a t(15;17) karyotype Achieved clinical complete remission within the past 1-2 months Prior induction therapy must have contained tretinoin No other acute myeloid leukemia diagnosis PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 mg/dL Transaminases no greater than 3 times upper limit of normal Renal: Creatinine less than 2 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: Ejection fraction normal or greater than 50% by echocardiogram or MUGA Other: No other concurrent active malignancy No other serious or life-threatening condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 4 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 1 week since prior retinoids Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior postremission therapy of any form
Sites / Locations
- Memorial Sloan-Kettering Cancer Center